Motley Fool Australia

Mayne Pharma Group Ltd (ASX: MYX) Share Price and News

52 Week Range
1 Year Return
(20 mins delayed)

() Chart and Price Data


Share Price
Previous Close
Day Change
Monthly Average Volume
52 Week Range -
Days Range -

Mayne Pharma Group Ltd (ASX: MYX) Latest News

Why the Mayne Pharma (ASX:MYX) share price is pushing higher

More »

asx shares impacted by china represented by hands printed with australian and chinese flags shaking

Which ASX shares will China ‘punish’ next?

More »

falling asx share price represented by woman making sad face

Mayne Pharma (ASX:MYX) share price falls on results update

More »

Doctor holding small world globe in one hand and a Covid vaccine needle in the other

2 ASX healthcare shares that have risen since Pfizer’s vaccine news

More »

falling asx share price represented by piggy bank wearing doctor's mask having fallen over

Mayne Pharma (ASX:MYX) share price dives 16% on FDA update

More »

Chalkboard Graph Up Dow

Why IAG, Mayne Pharma, Mesoblast, & Temple & Webster shares are tumbling lower

More »

shares higher, growth shares

The Mayne Pharma (ASX:MYX) share price leaps almost 8% higher

More »

graph of paper plane trending down

Why IDP Education, IRESS, Mosaic Brands, & Mayne Pharma are dropping lower

More »

Recent Stock Announcements

Price Sensitive Only$An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Show All
Date Heading $An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security. Time Pages File Size

About Mayne Pharma Group Ltd (ASX: MYX)

Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company that applies its drug delivery expertise to commercialise branded and generic pharmaceuticals. The company also provides contract development and manufacturing services to more than 100 clients worldwide.

Mayne Pharma is technology driven with a significant product portfolio and pipeline, and global reach through distribution partners in Australia, North America, Europe and Asia. The company has product development and manufacturing facilities in Salisbury, Australia and Greenville, North Carolina, USA with expertise in formulating complex oral and topical dose forms. The business is supported by more than 900 staff globally with more than 200 scientists employed.

The Salisbury facility is capable of developing products from formulation and clinical trial stages to validation and registration, right through to commercial scale manufacture of packaged goods.

Director Transactions

Data provided by Morningstar.
Date Director Type Amount Value Notes
04 Dec 2020 Scott Richards Issued 8 $3,072,000
04 Dec 2020 Scott Richards Issued 1 $405,177
01 Sep 2020 Frank Condella Buy 110 $37,287
31 Aug 2020 Scott Richards Cancelled 2 $855,421
11 Mar 2020 Bruce Mathieson Buy 3 $982,335
03 Mar 2020 Bruce Mathieson Buy 3 $1,170,433

Directors & Management

Data provided by Morningstar.
Name Title StartDate Profile
Mr Roger Campbell Corbett Non-Executive Director,Non-Executive Chairman Nov 2010
Mr Bruce L Mathieson Non-Executive Director Feb 2007
Mr Frank Condella Non-Executive Director May 2018
Mr Ian Frank Scholes Non-Executive Director Oct 2007
Ms Nancy Dolan Non-Executive Director Sep 2016
Mr Scott Anthony Richards Chief Executive Officer,Managing Director Feb 2012
Professor Bruce Gregory Robinson Non-Executive Director Aug 2014
Mr Patrick J Blake Non-Executive Director Jun 2018
Ms Laura Loftus Company Secretary Mar 2020
Laura Loftus Company Secretary
Kate Rintoul Executive Vice President and General Counsel
Daniel Moore Executive Vice President, Generic Products Division
Brant Schofield Executive Vice President, Specialty Brands Division
Peter Paltoglou Interim CFO and Chief Development Officer
Stefan Cross President, International Operations
John Ross President, Mayne Pharma USA
Andrew Herdman Vice President, Group Human Resources
Show more

Top Share Holders

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 320,478,060 19.10%
Mr Bruce Mathieson And Related Entities 105,577,583 6.30%
J P Morgan Nominees Australia Pty Limited 102,531,522 6.10%
Citicorp Nominees Pty Limited 97,467,463 5.80%
Solium Nominees (Australia) Pty Ltd <Bare Allocated A/C> 89,184,990 5.30%
Estetra Sprl 83,100,000 4.90%
Solium Nominees (Australia) Pty Ltd <Unallocated A/C> 29,692,951 1.80%
BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C> 26,688,048 1.60%
IVL Group Pty Ltd 16,000,000 1.00%
BNP Paribas Noms Pty Ltd <Drp> 14,106,094 0.80%
Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 14,100,000 0.80%
Australian Executor Trustees Limited <Ips Super A/C> 11,327,284 0.70%
Mr Roger Corbett And Related Entities 10,440,569 0.60%
National Nominees Limited 10,278,401 0.60%
Vivnat (Curtin) Pty Ltd 10,000,000 0.60%
Y S Chains Pty Ltd 10,000,000 0.60%
WAL Assets Pty Ltd <The La Wilson Property A/C> 9,193,503 0.50%
R & J Smith Shareholding Pty Ltd <R & J Smith Shareholding A/C> 8,853,084 0.50%
Mr Roger Aston & Related Entities 7,140,935 0.40%
William P Hodges 6,089,554 0.40%
Show more